Sign In
Buy ICCM
$3.54
-0.110 (-3.01%)
At Close: Jul 13, 2026
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
08:11am, Monday, 06'th Jul 2026
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cance
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:12am, Thursday, 25'th Jun 2026
CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describe
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro
IceCure Stock Surges After 70% ProSense Install Increase
12:45pm, Wednesday, 17'th Jun 2026
IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
08:25am, Wednesday, 17'th Jun 2026
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences c
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
08:30am, Tuesday, 02'nd Jun 2026
Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
04:30pm, Wednesday, 13'th May 2026
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or t
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
12:40pm, Tuesday, 12'th May 2026
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
10:41am, Tuesday, 12'th May 2026
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
08:30am, Tuesday, 12'th May 2026
Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Acc
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
08:30am, Wednesday, 06'th May 2026
CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys
As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year'
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massac
